# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION
# Washington, D.C. 20549

---

# FORM 8-K

---

## CURRENT REPORT

### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): March 2, 2017

**Akorn, Inc.**
(Exact Name of Registrant as Specified in Charter)

| **Louisiana** | **001-32360** | **72-0717400** |
|---|---|---|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |

**1925 W. Field Court, Suite 300, Lake Forest, Illinois 60045**
(Address of Principal Executive Offices) (Zip Code)

**(847) 279-6100**
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure.**

On March 2, 2017, Akorn, Inc. (Nasdaq: AKRX), a leading specialty generics pharmaceutical company, announced that it received approval from the U.S. Food and Drug Administration (FDA) of its New Drug Application (NDA) for Ephedrine Sulfate Injection, USP 50 mg/mL in 1 mL single dose ampule. Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 7.01, including exhibit 99.1 attached hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits. See attached exhibit index.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Akorn, Inc.**

Date: March 2, 2017

By: /s/ Duane A. Portwood
Duane A. Portwood
Chief Financial Officer

**Exhibit Index**

| Exhibit No. | Description of Exhibit |
| --- | --- |
| 99.1 | Press release dated March 2, 2017, issued by Akorn, Inc. entitled “Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP.” |

**EXHIBIT 99.1**

**Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP**

LAKE FOREST, Ill., March 02, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generics pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Ephedrine Sulfate Injection, USP 50 mg/mL in 1 mL single dose ampule. Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

**About Akorn**
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn's website at www.akorn.com.

Investors/Media:
Stephanie Carrington
ICR, Inc.
(646) 277-1282
Stephanie.carrington@icrinc.com